InflaRx (IFRX) Competitors $0.88 -0.02 (-1.69%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.89 +0.01 (+1.12%) As of 07/11/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. EDIT, DSGN, TVRD, SCPH, MDWD, KOD, ACIU, CRGX, LRMR, and CTMXShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Editas Medicine (EDIT), Design Therapeutics (DSGN), Tvardi Therapeutics (TVRD), scPharmaceuticals (SCPH), MediWound (MDWD), Kodiak Sciences (KOD), AC Immune (ACIU), CARGO Therapeutics (CRGX), Larimar Therapeutics (LRMR), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Its Competitors Editas Medicine Design Therapeutics Tvardi Therapeutics scPharmaceuticals MediWound Kodiak Sciences AC Immune CARGO Therapeutics Larimar Therapeutics CytomX Therapeutics InflaRx (NASDAQ:IFRX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Do institutionals and insiders believe in IFRX or EDIT? 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 2.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger earnings and valuation, IFRX or EDIT? InflaRx has higher earnings, but lower revenue than Editas Medicine. InflaRx is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$129.75K455.36-$49.85M-$0.82-1.07Editas Medicine$32.31M7.46-$237.09M-$3.04-0.95 Does the media favor IFRX or EDIT? In the previous week, InflaRx had 5 more articles in the media than Editas Medicine. MarketBeat recorded 7 mentions for InflaRx and 2 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.61 beat InflaRx's score of 0.90 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is IFRX or EDIT more profitable? InflaRx has a net margin of 0.00% compared to Editas Medicine's net margin of -701.06%. InflaRx's return on equity of -64.17% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -64.17% -53.39% Editas Medicine -701.06%-139.24%-63.87% Do analysts recommend IFRX or EDIT? InflaRx currently has a consensus target price of $6.60, indicating a potential upside of 649.91%. Editas Medicine has a consensus target price of $4.70, indicating a potential upside of 63.19%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Editas Medicine 2 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.31 Which has more risk and volatility, IFRX or EDIT? InflaRx has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. SummaryInflaRx beats Editas Medicine on 11 of the 17 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.08M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-1.0720.8528.2620.26Price / Sales455.36303.05437.10166.10Price / CashN/A42.1137.1257.67Price / Book0.787.638.045.49Net Income-$49.85M-$55.05M$3.19B$250.45M7 Day Performance9.33%8.43%3.62%4.79%1 Month Performance12.26%8.14%5.98%9.59%1 Year Performance-46.01%1.62%29.39%16.41% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.7976 of 5 stars$0.88-1.7%$6.60+649.9%-46.7%$59.08M$129.75K-1.0760News CoverageHigh Trading VolumeEDITEditas Medicine4.2503 of 5 stars$2.54-1.2%$4.70+85.0%-48.0%$215.14M$32.31M-0.84230Positive NewsDSGNDesign Therapeutics0.6325 of 5 stars$3.54-6.1%$4.00+13.0%-10.1%$214.02MN/A-3.5840News CoverageTVRDTvardi TherapeuticsN/A$21.52-4.2%$71.50+232.2%N/A$210.25M$7.14M0.0080News CoverageAnalyst ForecastAnalyst RevisionGap UpSCPHscPharmaceuticals4.4252 of 5 stars$3.86-2.8%$14.00+262.7%-3.3%$209.58M$36.33M-2.0230Positive NewsMDWDMediWound1.8367 of 5 stars$19.27-0.4%$31.80+65.0%-5.3%$209.02M$20.22M-9.2280KODKodiak Sciences4.0879 of 5 stars$3.71-6.1%$9.00+142.6%+51.0%$208.42MN/A-1.0290News CoverageACIUAC Immune2.2547 of 5 stars$1.99-3.9%$12.00+503.0%-44.0%$207.85M$31.02M-3.43140Analyst RevisionCRGXCARGO Therapeutics2.2339 of 5 stars$4.39-1.6%$15.00+241.7%-74.1%$205.65MN/A-0.95116News CoverageAnalyst ForecastLRMRLarimar Therapeutics2.0079 of 5 stars$3.20flat$18.50+478.1%-67.8%$204.89MN/A-2.1530Gap DownCTMXCytomX Therapeutics4.2745 of 5 stars$2.37-5.2%$5.33+125.0%+70.4%$201.55M$138.10M4.94170News CoveragePositive News Related Companies and Tools Related Companies Editas Medicine Competitors Design Therapeutics Competitors Tvardi Therapeutics Competitors scPharmaceuticals Competitors MediWound Competitors Kodiak Sciences Competitors AC Immune Competitors CARGO Therapeutics Competitors Larimar Therapeutics Competitors CytomX Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
